BRAF mutation and gene methylation frequencies of colorectal tumours with microsatellite instability increase markedly with patient age [11]

Gut

Volumn 55, Issue 8, 2006, Pages 1213-1214

  Iacopetta, B ^a,d   Li, W Q ^a   Grieu, F ^a   Ruszkiewicz, A ^b   Kawakami, K ^c  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^c KANAZAWA UNIV SCHOOL OF MEDICINE   (Japan)

^d Ear Science Institute Australia   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; FLUOROURACIL;

AGING; COLORECTAL CANCER; GENE MUTATION; HUMAN; LETTER; METHYLATION; MICROSATELLITE INSTABILITY; PRIORITY JOURNAL;

ADULT; AGE FACTORS; AGED; COLORECTAL NEOPLASMS; DNA METHYLATION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MICROSATELLITE REPEATS; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 33746110875     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2006.095455     Document Type: Letter

References (10)

1. Jass JR, Walsh MD, Barker M, et al. Distinction between familial and sporadic forms of colorectal cancer showing DNA microsatellite instability. Eur J Cancer 2002;38:858-66.
2. Jass JR. HNPCC and sporadic MSI-H colorectal cancer: a review of the morphological similarities and differences. Fam Cancer 2004;3:93-100.
3. Deng G, Bell I, Crawley S, et al. BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res 2004;10:191-5.
4. McGivern A, Wynter CV, Whitehall VL, et al. Promoter hypermethylation frequency and BRAF mutations distinguish hereditary non-polyposis colon cancer from sporadic MSI-H colon cancer. Fam Cancer 2004;3:101-7.
5. Samowitz WS, Sweeney C, Herrick J, et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 2005;65:6063-9.
6. Malkhosyan SR, Yamamoto H, Piao Z, et al. Late onset and high incidence of colon cancer of the mutator phenotype with hypermethylated hMLH1 gene in women. Gastroenterology 2000;119:598.
7. Elsaleh H, Powell B, McCaul K, et al. P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma. Clin Cancer Res 2001;7:1343-9.
8. Watanabe T, Wu TT, Catalano PJ, et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001;344:1196-206.
9. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instabillty status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003;349:247-57.
10. Carethers JM, Smith FJ, Behling CA, et al. Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology 2004;126:394-401.